Novartis Reports P-III Trial (NETTER-2) Results of Lutathera as 1L Advanced Gastroenteropancreatic Neuroendocrine Tumors
Shots:
- The P-III trial (NETTER-2) evaluating Lutathera + long-acting octreotide in 222 patients with newly diagnosed somatostatin receptor (SSTR)-positive, grade 2 & 3, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
- The trial met its 1EPs & demonstrated a significant improvement in PFS over high-dose long-acting octreotide alone while no new or unexpected safety findings were seen and the results were consistent with the well-established safety profile of Lutathera
- The results will be presented at an upcoming medical meeting and discussed with regulatory authorities. Lutathera, an advanced accelerator applications RLT was approved in the US for SSTR+ GEP-NETs
Ref: Globenewswire | Image: Novartis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
